Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call.
Bioventus (BVS) Matches Q3 Earnings Estimates
Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
Bioventus Surges 73% in Three Months: Time to Buy the Stock?
BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
Bull Of The Day: Bioventus (BVS)
This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion.
Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS ) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Here's Why You Should Consider Buying Bioventus (BVS) Stock
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
3 Stocks Under $10 With Mammoth Growth Prospects
Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential.
